Molecular subtypes of pancreatic cancer

Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Gastroenterology & hepatology Jg. 16; H. 4; S. 207 - 220
Hauptverfasser: Collisson, Eric A., Bailey, Peter, Chang, David K., Biankin, Andrew V.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 01.04.2019
Nature Publishing Group
Schlagworte:
ISSN:1759-5045, 1759-5053, 1759-5053
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies using molecular taxonomy to guide therapeutic development and therapy with the overall goal of improving outcomes for this disease. Key points Pancreatic cancer is soon to become the second leading cause of cancer-related death. Histopathological criteria do not adequately inform treatment decisions for pancreatic cancer. A molecular taxonomy could improve outcomes with current treatments and accelerate therapeutic development through better patient selection. Emerging molecular taxonomies define biological differences between subtypes that are associated with prognosis. Genomic and transcriptomic subtypes potentially enrich for therapeutic vulnerabilities and require preclinical and clinical assessment.
AbstractList Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies using molecular taxonomy to guide therapeutic development and therapy with the overall goal of improving outcomes for this disease. Key points Pancreatic cancer is soon to become the second leading cause of cancer-related death. Histopathological criteria do not adequately inform treatment decisions for pancreatic cancer. A molecular taxonomy could improve outcomes with current treatments and accelerate therapeutic development through better patient selection. Emerging molecular taxonomies define biological differences between subtypes that are associated with prognosis. Genomic and transcriptomic subtypes potentially enrich for therapeutic vulnerabilities and require preclinical and clinical assessment.
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies using molecular taxonomy to guide therapeutic development and therapy with the overall goal of improving outcomes for this disease.
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies using molecular taxonomy to guide therapeutic development and therapy with the overall goal of improving outcomes for this disease. Key points Pancreatic cancer is soon to become the second leading cause of cancer-related death. Histopathological criteria do not adequately inform treatment decisions for pancreatic cancer. A molecular taxonomy could improve outcomes with current treatments and accelerate therapeutic development through better patient selection. Emerging molecular taxonomies define biological differences between subtypes that are associated with prognosis. Genomic and transcriptomic subtypes potentially enrich for therapeutic vulnerabilities and require preclinical and clinical assessment.
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.
Audience Academic
Author Bailey, Peter
Chang, David K.
Collisson, Eric A.
Biankin, Andrew V.
Author_xml – sequence: 1
  givenname: Eric A.
  surname: Collisson
  fullname: Collisson, Eric A.
  organization: University of California, San Francisco
– sequence: 2
  givenname: Peter
  surname: Bailey
  fullname: Bailey, Peter
  organization: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate
– sequence: 3
  givenname: David K.
  surname: Chang
  fullname: Chang, David K.
  organization: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, West of Scotland Pancreatic Unit, Glasgow Royal Infirmary
– sequence: 4
  givenname: Andrew V.
  orcidid: 0000-0002-0362-5597
  surname: Biankin
  fullname: Biankin, Andrew V.
  email: andrew.biankin@glasgow.ac.uk
  organization: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30718832$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1P3DAQhq0K1AXaH9BLtVKlwiXUju04PiLElwTiQs-W40wWr7zx1k4O--870QJbUEGjkUfW8868mjkke33sgZBvjJ4yyutfWTCpZEGZxqS62HwiB0xJXUgq-d5LLeSMHOa8pLSSkuvPZMapYnXNywNyfBcDuDHYNM9jM2zWkOexm69t7xLYwbu5wxLSF7Lf2ZDh69N7RH5fXjycXxe391c352e3hROKDoUtG4bhMFslqdWNaJ3rbKOEpOgTlK0qqFpNXVcDSKvqRnOoRFmzTjnFj8jJtu86xT8j5MGsfHYQgu0hjtmUTGnJWcUn9McbdBnH1KM7pHQtpWBM7qiFDWB838UhWTc1NWeyxi1SIQRSp_-hMFpYeYdb7zz-vxL8_EfwCDYMjzmGcfCxz6_B708ux2YFrVknv7JpY55PgADbAi7FnBN0LwijZjqz2Z7Z4PrMdGazQY16o3F-sNNstO3Dh8pyq8w4pV9A2i3tfdFfKKi4DA
CitedBy_id crossref_primary_10_1371_journal_pone_0222139
crossref_primary_10_1016_j_pathol_2021_09_012
crossref_primary_10_3390_cancers16162876
crossref_primary_10_1016_j_hbpd_2024_03_002
crossref_primary_10_3390_cancers14061518
crossref_primary_10_1186_s13073_020_00734_5
crossref_primary_10_1007_s00292_021_00965_2
crossref_primary_10_1016_j_pan_2022_11_008
crossref_primary_10_3390_cancers17121979
crossref_primary_10_3389_fphar_2024_1505027
crossref_primary_10_1016_j_heliyon_2021_e06000
crossref_primary_10_3389_fonc_2022_806963
crossref_primary_10_3390_biomedicines11092569
crossref_primary_10_1016_j_ygeno_2021_11_036
crossref_primary_10_1245_s10434_023_13281_1
crossref_primary_10_3390_cancers14061523
crossref_primary_10_1016_j_esmogo_2024_100070
crossref_primary_10_1016_j_isci_2024_110880
crossref_primary_10_1158_1078_0432_CCR_23_0825
crossref_primary_10_1186_s12885_020_07426_8
crossref_primary_10_1002_advs_202201992
crossref_primary_10_1016_j_ccell_2023_09_008
crossref_primary_10_1002_path_6268
crossref_primary_10_3389_fcell_2021_691161
crossref_primary_10_3389_fimmu_2024_1347683
crossref_primary_10_1002_advs_202002178
crossref_primary_10_1172_JCI151601
crossref_primary_10_1093_hmg_ddae042
crossref_primary_10_3390_jcm8060903
crossref_primary_10_3389_fimmu_2024_1454823
crossref_primary_10_3748_wjg_v27_i20_2507
crossref_primary_10_3389_fcell_2022_1001606
crossref_primary_10_1097_SLA_0000000000005050
crossref_primary_10_3390_ijms25168665
crossref_primary_10_1016_j_bbrc_2023_06_062
crossref_primary_10_1002_adhm_202201907
crossref_primary_10_1016_j_semcancer_2024_09_002
crossref_primary_10_1155_2020_1570862
crossref_primary_10_1016_j_cell_2023_02_014
crossref_primary_10_1016_j_hpb_2024_02_001
crossref_primary_10_3390_md19110588
crossref_primary_10_1089_pancan_2019_0014
crossref_primary_10_1002_1878_0261_13625
crossref_primary_10_3390_cancers17183085
crossref_primary_10_1016_j_modpat_2023_100251
crossref_primary_10_1002_1878_0261_13747
crossref_primary_10_1002_jcsm_12627
crossref_primary_10_3390_ijms21207437
crossref_primary_10_1016_j_ejso_2020_06_028
crossref_primary_10_1073_pnas_2005156117
crossref_primary_10_3390_cancers13194984
crossref_primary_10_1186_s40164_020_00179_x
crossref_primary_10_3390_ijms241914979
crossref_primary_10_1109_TCBB_2021_3106344
crossref_primary_10_1002_jso_26395
crossref_primary_10_3390_cancers14153709
crossref_primary_10_1158_1078_0432_CCR_21_1220
crossref_primary_10_3390_ijms21103534
crossref_primary_10_1038_s41467_021_23237_2
crossref_primary_10_1016_j_jbc_2024_107710
crossref_primary_10_1016_j_devcel_2022_04_014
crossref_primary_10_1016_j_critrevonc_2021_103428
crossref_primary_10_1016_j_isci_2024_111662
crossref_primary_10_1096_fj_202000363RR
crossref_primary_10_1038_s41586_022_04888_7
crossref_primary_10_1186_s12876_023_02748_w
crossref_primary_10_3390_cancers16020359
crossref_primary_10_1038_s41392_023_01376_w
crossref_primary_10_1002_path_6293
crossref_primary_10_1038_s12276_022_00882_1
crossref_primary_10_3389_fonc_2022_800140
crossref_primary_10_3390_cancers13246354
crossref_primary_10_3390_ijms26115242
crossref_primary_10_1097_JP9_0000000000000109
crossref_primary_10_1134_S0026893324700432
crossref_primary_10_3389_fonc_2021_751311
crossref_primary_10_1002_cam4_70538
crossref_primary_10_1016_j_hpb_2020_01_005
crossref_primary_10_1136_jitc_2021_002876
crossref_primary_10_3390_cancers16081456
crossref_primary_10_3389_fimmu_2023_1216376
crossref_primary_10_1016_j_stem_2023_12_010
crossref_primary_10_1038_s44220_024_00217_1
crossref_primary_10_1371_journal_pone_0255397
crossref_primary_10_3390_ijms24010156
crossref_primary_10_1016_j_heliyon_2024_e36434
crossref_primary_10_1136_gutjnl_2021_325564
crossref_primary_10_1038_s41467_025_60129_1
crossref_primary_10_1186_s12964_019_0435_2
crossref_primary_10_1007_s00018_022_04638_y
crossref_primary_10_1016_j_ebiom_2021_103541
crossref_primary_10_1158_1078_0432_CCR_20_2831
crossref_primary_10_1097_JS9_0000000000001762
crossref_primary_10_1158_1078_0432_CCR_21_3452
crossref_primary_10_3389_fonc_2022_1045477
crossref_primary_10_1590_s0102_865020200050000008
crossref_primary_10_3390_jpm15060221
crossref_primary_10_1080_14728222_2019_1606904
crossref_primary_10_5306_wjco_v13_i10_762
crossref_primary_10_1158_1078_0432_CCR_20_3925
crossref_primary_10_1038_s41598_023_36413_9
crossref_primary_10_1038_s41591_023_02790_x
crossref_primary_10_1007_s41971_019_00062_5
crossref_primary_10_1038_s41467_023_41861_y
crossref_primary_10_1111_eva_70091
crossref_primary_10_1007_s00535_024_02103_0
crossref_primary_10_1038_s41598_024_65194_y
crossref_primary_10_1016_j_drup_2021_100779
crossref_primary_10_1051_e3sconf_202127103052
crossref_primary_10_3390_cancers16122270
crossref_primary_10_3390_cells13070602
crossref_primary_10_1007_s00535_025_02272_6
crossref_primary_10_1007_s13402_023_00870_1
crossref_primary_10_1097_MD_0000000000024969
crossref_primary_10_1002_gcc_22932
crossref_primary_10_1007_s10396_023_01403_x
crossref_primary_10_3390_cancers17152453
crossref_primary_10_2217_epi_2022_0177
crossref_primary_10_1016_j_ctarc_2024_100804
crossref_primary_10_1158_1078_0432_CCR_22_2576
crossref_primary_10_3390_cancers12061440
crossref_primary_10_1158_0008_5472_CAN_21_4362
crossref_primary_10_1021_acs_analchem_4c07031
crossref_primary_10_1080_14737159_2024_2348676
crossref_primary_10_1038_s41392_021_00659_4
crossref_primary_10_1038_s41416_020_01119_6
crossref_primary_10_1002_1878_0261_12743
crossref_primary_10_1158_0008_5472_CAN_20_3855
crossref_primary_10_1158_1078_0432_CCR_20_4712
crossref_primary_10_3389_fonc_2022_827259
crossref_primary_10_3390_cells11030426
crossref_primary_10_5937_jomb0_38840
crossref_primary_10_1080_17474124_2021_1967144
crossref_primary_10_3389_fimmu_2025_1573522
crossref_primary_10_1016_j_canlet_2024_216650
crossref_primary_10_1053_j_gastro_2020_09_043
crossref_primary_10_3389_fonc_2024_1301059
crossref_primary_10_4251_wjgo_v11_i11_933
crossref_primary_10_21294_1814_4861_2025_24_3_149_161
crossref_primary_10_1186_s12967_021_02972_6
crossref_primary_10_1158_0008_5472_CAN_20_0672
crossref_primary_10_1002_1878_0261_12835
crossref_primary_10_1073_pnas_2105691119
crossref_primary_10_3389_fphar_2024_1444733
crossref_primary_10_3390_cancers12092346
crossref_primary_10_1002_cpt_1796
crossref_primary_10_1016_j_isci_2025_113012
crossref_primary_10_1016_j_omto_2020_08_019
crossref_primary_10_3390_genes13101913
crossref_primary_10_1186_s12935_021_02324_w
crossref_primary_10_1016_j_canlet_2024_216873
crossref_primary_10_3389_fcell_2021_753456
crossref_primary_10_3390_cancers14163950
crossref_primary_10_3892_ijo_2022_5456
crossref_primary_10_1016_j_humgen_2024_201371
crossref_primary_10_1038_s41571_025_01019_9
crossref_primary_10_1007_s11864_023_01096_x
crossref_primary_10_3389_fimmu_2025_1563725
crossref_primary_10_3390_jpm12030478
crossref_primary_10_1016_j_hpr_2024_300741
crossref_primary_10_1038_s41598_022_07628_z
crossref_primary_10_1016_j_ebiom_2024_105278
crossref_primary_10_3390_cancers13071608
crossref_primary_10_3389_fcell_2025_1629683
crossref_primary_10_3389_fcell_2022_936168
crossref_primary_10_1002_2056_4538_12377
crossref_primary_10_1016_j_canlet_2023_216147
crossref_primary_10_1016_j_ccell_2020_09_010
crossref_primary_10_1016_j_arabjc_2024_105990
crossref_primary_10_3390_jpm12122005
crossref_primary_10_1053_j_gastro_2021_04_082
crossref_primary_10_1016_j_critrevonc_2023_104013
crossref_primary_10_1038_s41416_024_02803_7
crossref_primary_10_1002_jso_28044
crossref_primary_10_1038_s41420_025_02674_8
crossref_primary_10_1186_s13046_024_03066_z
crossref_primary_10_3389_fimmu_2023_1163585
crossref_primary_10_3390_cancers14153799
crossref_primary_10_7717_peerj_17350
crossref_primary_10_1136_gutjnl_2022_327855
crossref_primary_10_1016_j_cellsig_2024_111381
crossref_primary_10_3390_biomedicines12102175
crossref_primary_10_1038_s41388_022_02432_5
crossref_primary_10_2147_OTT_S265036
crossref_primary_10_1016_j_canlet_2021_11_016
crossref_primary_10_1038_s41551_024_01273_9
crossref_primary_10_3390_medicina58091298
crossref_primary_10_3389_fonc_2022_932786
crossref_primary_10_1038_s41467_025_58718_1
crossref_primary_10_5812_ijpr_137226
crossref_primary_10_1158_1078_0432_CCR_19_3724
crossref_primary_10_1007_s12033_023_00923_8
crossref_primary_10_3390_ijms21165656
crossref_primary_10_1002_jat_4494
crossref_primary_10_1136_gutjnl_2020_322814
crossref_primary_10_1186_s12967_023_04045_2
crossref_primary_10_1016_j_carbpol_2024_121889
crossref_primary_10_1111_jcmm_14894
crossref_primary_10_1016_j_cell_2021_08_023
crossref_primary_10_1016_j_omtn_2021_06_015
crossref_primary_10_1002_ijc_34960
crossref_primary_10_3390_cancers11081136
crossref_primary_10_3389_fonc_2020_584330
crossref_primary_10_1371_journal_pone_0247752
crossref_primary_10_1186_s12943_025_02374_y
crossref_primary_10_1186_s12943_022_01538_4
crossref_primary_10_1111_jcmm_17852
crossref_primary_10_1038_s41556_024_01498_5
crossref_primary_10_1155_2020_8758090
crossref_primary_10_1016_j_bbcan_2023_189065
crossref_primary_10_3892_etm_2021_10708
crossref_primary_10_1038_s41467_022_32806_y
crossref_primary_10_3389_fphar_2022_904448
crossref_primary_10_1053_j_gastro_2021_03_051
crossref_primary_10_3389_fonc_2025_1538335
crossref_primary_10_1007_s10565_020_09562_0
crossref_primary_10_1016_j_labinv_2025_104191
crossref_primary_10_1371_journal_pone_0329946
crossref_primary_10_3389_fonc_2025_1636715
crossref_primary_10_3390_cancers14163994
crossref_primary_10_1097_SLA_0000000000004200
crossref_primary_10_1016_j_critrevonc_2024_104362
crossref_primary_10_1007_s00259_023_06115_5
crossref_primary_10_1016_j_ajur_2024_09_006
crossref_primary_10_1016_j_omton_2025_201047
crossref_primary_10_1016_j_crmeth_2022_100340
crossref_primary_10_3390_ijms21228841
crossref_primary_10_3389_fcell_2020_00308
crossref_primary_10_1016_j_modpat_2023_100328
crossref_primary_10_1158_1541_7786_MCR_24_0785
crossref_primary_10_1016_j_semradonc_2025_08_004
crossref_primary_10_3390_diagnostics13020215
crossref_primary_10_1016_j_jep_2025_119893
crossref_primary_10_3390_biomedicines11020252
crossref_primary_10_1016_j_canlet_2024_216663
crossref_primary_10_1002_cam4_3695
crossref_primary_10_1053_j_gastro_2021_04_044
crossref_primary_10_3390_cells13050395
crossref_primary_10_1371_journal_pone_0230060
crossref_primary_10_3389_fgene_2021_702072
crossref_primary_10_1097_MPA_0000000000001853
crossref_primary_10_3390_cancers16010002
crossref_primary_10_3390_cancers12071872
crossref_primary_10_1158_1078_0432_CCR_20_2667
crossref_primary_10_1158_1078_0432_CCR_20_3513
crossref_primary_10_3389_fdata_2021_568352
crossref_primary_10_1007_s13402_023_00836_3
crossref_primary_10_1038_s41598_025_02096_7
crossref_primary_10_1186_s12887_024_05378_7
crossref_primary_10_1038_s41598_025_05346_w
crossref_primary_10_3390_ijms23094792
crossref_primary_10_1016_j_yao_2021_02_006
crossref_primary_10_5858_arpa_2023_0005_OA
crossref_primary_10_15252_embj_2020107206
crossref_primary_10_1158_2159_8290_CD_20_1098
crossref_primary_10_1016_j_ctarc_2025_100939
crossref_primary_10_1002_advs_202309387
crossref_primary_10_1177_17588359211038478
crossref_primary_10_1158_2159_8290_CD_20_1090
crossref_primary_10_1186_s13046_020_01765_x
crossref_primary_10_1038_s41379_022_01143_2
crossref_primary_10_3892_mmr_2021_12459
crossref_primary_10_1016_j_celrep_2025_116191
crossref_primary_10_1038_s41467_022_29857_6
crossref_primary_10_3390_ijms24065113
crossref_primary_10_1080_21645515_2025_2538330
crossref_primary_10_1016_j_ajpath_2020_03_020
crossref_primary_10_1007_s12672_022_00550_w
crossref_primary_10_1038_s43018_019_0010_1
crossref_primary_10_1158_2159_8290_CD_20_0133
crossref_primary_10_3389_fonc_2020_01052
crossref_primary_10_3390_ijms232315011
crossref_primary_10_1038_s43018_022_00478_8
crossref_primary_10_1186_s13148_021_01090_w
crossref_primary_10_3390_metabo12050409
crossref_primary_10_1053_j_seminoncol_2021_02_003
crossref_primary_10_1186_s13046_022_02301_9
crossref_primary_10_3390_cancers12071825
crossref_primary_10_1002_adtp_202000003
crossref_primary_10_15252_embj_2020104759
crossref_primary_10_3390_cancers13174451
crossref_primary_10_1186_s13046_021_02055_w
crossref_primary_10_1158_0008_5472_CAN_22_3219
crossref_primary_10_3389_fimmu_2025_1586784
crossref_primary_10_3390_biom12050652
crossref_primary_10_15252_embj_2023114282
crossref_primary_10_3390_cells10071821
crossref_primary_10_1038_s41467_023_38171_8
crossref_primary_10_1016_j_pharmthera_2025_108847
crossref_primary_10_3390_cancers17060957
crossref_primary_10_3390_cancers12041024
crossref_primary_10_1016_j_hbpd_2021_09_004
crossref_primary_10_1016_j_immuni_2024_05_015
crossref_primary_10_1158_1078_0432_CCR_20_2475
crossref_primary_10_1186_s13073_024_01287_7
crossref_primary_10_1007_s12029_025_01183_2
crossref_primary_10_1097_JP9_0000000000000093
crossref_primary_10_1016_j_canlet_2023_216421
crossref_primary_10_1002_cam4_6800
crossref_primary_10_3389_fphar_2022_837503
crossref_primary_10_1016_j_ejca_2023_112940
crossref_primary_10_1016_j_addr_2025_115652
crossref_primary_10_1200_EDBK_280901
crossref_primary_10_3390_ijms222413408
crossref_primary_10_1038_s43018_022_00479_7
crossref_primary_10_2147_DNND_S491211
crossref_primary_10_1038_s41598_023_43577_x
crossref_primary_10_3748_wjg_v27_i17_1883
crossref_primary_10_1002_advs_202307695
crossref_primary_10_1038_s41598_021_94150_3
crossref_primary_10_1016_j_cellsig_2023_110774
crossref_primary_10_1016_j_annonc_2020_11_013
crossref_primary_10_1186_s12885_023_10658_z
crossref_primary_10_1016_j_hpb_2023_11_010
crossref_primary_10_1038_s41467_021_26059_4
crossref_primary_10_1038_s41388_022_02182_4
crossref_primary_10_1017_pcm_2023_2
crossref_primary_10_7554_eLife_53381
crossref_primary_10_1016_j_clim_2024_110333
crossref_primary_10_3390_ijms26167695
crossref_primary_10_1097_JS9_0000000000001293
crossref_primary_10_2217_imt_2020_0344
crossref_primary_10_1016_j_pan_2022_07_010
crossref_primary_10_3390_cancers15245842
crossref_primary_10_1038_s41388_022_02448_x
crossref_primary_10_3390_cimb47010027
crossref_primary_10_3389_fimmu_2021_719105
crossref_primary_10_1038_s41392_022_01152_2
crossref_primary_10_1038_s41598_024_68648_5
crossref_primary_10_1007_s10142_023_01122_z
crossref_primary_10_3390_cancers11081095
crossref_primary_10_4251_wjgo_v16_i12_4738
crossref_primary_10_1158_1078_0432_CCR_19_1496
crossref_primary_10_1158_1078_0432_CCR_20_4116
crossref_primary_10_1186_s12876_025_03918_8
crossref_primary_10_3389_fcell_2021_748631
crossref_primary_10_3390_cancers14122879
crossref_primary_10_1038_s41588_024_01890_9
crossref_primary_10_3390_molecules27144452
crossref_primary_10_1007_s10555_021_09989_9
crossref_primary_10_1016_j_isci_2025_112230
crossref_primary_10_1158_0008_5472_CAN_19_3922
crossref_primary_10_3389_fimmu_2021_643529
crossref_primary_10_3389_fimmu_2022_939836
crossref_primary_10_1016_j_semcancer_2024_12_003
crossref_primary_10_3390_cancers14235797
crossref_primary_10_3748_wjg_v27_i23_3158
crossref_primary_10_15252_emmm_202114876
crossref_primary_10_1080_14728222_2022_2021397
crossref_primary_10_3389_fimmu_2022_1031184
crossref_primary_10_1007_s00104_020_01169_9
crossref_primary_10_1097_MPA_0000000000002205
crossref_primary_10_1038_s41568_023_00648_5
crossref_primary_10_32604_or_2023_028905
crossref_primary_10_1158_1078_0432_CCR_23_0346
crossref_primary_10_1186_s13550_021_00808_4
crossref_primary_10_3389_fonc_2025_1616968
crossref_primary_10_3390_cancers13174376
crossref_primary_10_1007_s00535_023_02024_4
crossref_primary_10_12998_wjcc_v9_i19_4998
crossref_primary_10_1111_jcmm_17109
crossref_primary_10_3389_fcell_2021_795735
crossref_primary_10_1038_s41418_022_01102_z
crossref_primary_10_1073_pnas_1921484117
crossref_primary_10_1155_2020_8537381
crossref_primary_10_1007_s11427_024_2622_1
crossref_primary_10_1038_s41420_024_01866_y
crossref_primary_10_1055_a_2231_8475
crossref_primary_10_1038_s41467_019_12517_7
crossref_primary_10_3389_fonc_2022_827051
crossref_primary_10_1007_s12672_024_01628_3
crossref_primary_10_3389_fonc_2023_1112104
crossref_primary_10_1038_s42003_023_04461_6
crossref_primary_10_1002_advs_202306298
crossref_primary_10_1080_21691401_2019_1671856
crossref_primary_10_1038_s41525_020_00159_4
crossref_primary_10_1097_MPA_0000000000002301
crossref_primary_10_2147_IJN_S253599
crossref_primary_10_1007_s11864_025_01352_2
crossref_primary_10_3390_biom15030426
crossref_primary_10_1038_s41598_024_52646_8
crossref_primary_10_12688_f1000research_131414_1
crossref_primary_10_2147_OTT_S232464
crossref_primary_10_1186_s10020_024_01049_6
crossref_primary_10_3390_biomedicines10040926
crossref_primary_10_1016_j_pan_2023_10_021
crossref_primary_10_1080_17425255_2019_1620731
crossref_primary_10_1016_j_jhep_2020_03_008
crossref_primary_10_1016_j_pec_2023_108125
crossref_primary_10_1016_j_cell_2021_11_017
crossref_primary_10_1016_j_bbcan_2021_188554
crossref_primary_10_3390_proteomes11030024
crossref_primary_10_1007_s10555_023_10116_z
crossref_primary_10_1038_s41418_023_01168_3
crossref_primary_10_1136_gutjnl_2022_329313
crossref_primary_10_1016_S2468_1253_19_30175_X
crossref_primary_10_1159_000521714
crossref_primary_10_3390_cancers16101808
crossref_primary_10_1016_j_ijpharm_2020_120139
crossref_primary_10_1016_j_pan_2024_11_016
crossref_primary_10_1016_j_heliyon_2024_e28243
crossref_primary_10_3390_ijms23105459
crossref_primary_10_1016_j_bbcan_2020_188360
crossref_primary_10_1159_000519755
crossref_primary_10_3390_epigenomes8040041
crossref_primary_10_1186_s12859_024_05981_6
crossref_primary_10_1016_j_molmed_2024_11_007
crossref_primary_10_3389_fimmu_2023_1189161
crossref_primary_10_1186_s40170_024_00357_z
crossref_primary_10_1109_TCBB_2023_3300102
crossref_primary_10_1155_2022_7117014
crossref_primary_10_1038_s43018_023_00526_x
crossref_primary_10_1007_s00595_020_02028_0
crossref_primary_10_1016_j_neo_2025_101143
crossref_primary_10_3390_cells11193170
crossref_primary_10_3390_ijms25031389
crossref_primary_10_1136_gutjnl_2018_317856
crossref_primary_10_1007_s10555_021_09995_x
crossref_primary_10_3389_fphar_2021_781033
crossref_primary_10_1016_j_pan_2022_05_006
crossref_primary_10_1111_jcmm_16281
crossref_primary_10_3390_ijms22126374
crossref_primary_10_3390_cancers13123040
crossref_primary_10_1158_2159_8290_CD_23_1480
crossref_primary_10_1158_1078_0432_CCR_21_0640
crossref_primary_10_3389_fonc_2023_1047377
crossref_primary_10_3390_cancers14040897
crossref_primary_10_1002_ijc_33041
crossref_primary_10_1007_s10585_019_09996_9
crossref_primary_10_3390_ijms232314566
crossref_primary_10_1016_j_phymed_2024_155527
crossref_primary_10_1080_14789450_2020_1803743
crossref_primary_10_1016_j_ccell_2024_02_017
crossref_primary_10_1016_j_tranon_2021_101288
crossref_primary_10_3390_cancers12123635
crossref_primary_10_1007_s10637_024_01474_8
crossref_primary_10_1186_s12885_021_08952_9
crossref_primary_10_5812_hepatmon_118535
crossref_primary_10_1002_jso_26415
crossref_primary_10_1016_j_intimp_2021_107508
crossref_primary_10_1186_s13148_020_00878_6
crossref_primary_10_1007_s00330_022_09057_y
crossref_primary_10_3389_fcell_2022_886153
crossref_primary_10_1093_bib_bbae108
crossref_primary_10_3892_etm_2022_11430
crossref_primary_10_1016_j_devcel_2025_07_002
crossref_primary_10_1038_s41419_022_04573_7
crossref_primary_10_1186_s12935_021_01824_z
crossref_primary_10_1002_cjp2_323
crossref_primary_10_1016_j_canlet_2022_215694
crossref_primary_10_3390_genes11010006
crossref_primary_10_3390_nu16172889
crossref_primary_10_3390_cells11193068
crossref_primary_10_1038_s41467_023_36296_4
crossref_primary_10_1016_j_semdp_2025_150948
crossref_primary_10_3390_cancers12051227
crossref_primary_10_3390_cells11091472
crossref_primary_10_1016_j_bbcan_2022_188751
crossref_primary_10_1038_s41379_020_0629_6
crossref_primary_10_1093_bib_bbad282
crossref_primary_10_1016_j_ccell_2024_09_001
crossref_primary_10_3390_cancers13205126
crossref_primary_10_1016_j_ctrv_2019_101926
crossref_primary_10_1186_s13045_020_00958_3
crossref_primary_10_3389_fonc_2024_1405612
crossref_primary_10_3390_cancers15030970
crossref_primary_10_1093_carcin_bgae011
crossref_primary_10_1158_2159_8290_CD_20_0633
crossref_primary_10_1038_s41698_025_00848_2
crossref_primary_10_1016_j_csbj_2022_08_064
crossref_primary_10_1080_14756366_2025_2538673
crossref_primary_10_1016_j_phymed_2023_154990
crossref_primary_10_3390_jcm10010149
crossref_primary_10_1002_cam4_7189
crossref_primary_10_1038_s41588_024_01790_y
crossref_primary_10_1186_s12864_024_09964_y
crossref_primary_10_1186_s12859_021_04381_4
crossref_primary_10_3390_jcm9030724
crossref_primary_10_1016_j_molcel_2020_06_009
crossref_primary_10_1186_s12935_021_01812_3
crossref_primary_10_1007_s10147_021_01983_z
crossref_primary_10_1158_1078_0432_CCR_21_0775
crossref_primary_10_3389_fonc_2022_995357
crossref_primary_10_3390_cancers16203439
crossref_primary_10_1155_2022_4661929
crossref_primary_10_3390_cancers16234094
crossref_primary_10_1631_jzus_B2300457
crossref_primary_10_3390_cancers15051442
crossref_primary_10_1007_s00795_025_00435_1
crossref_primary_10_1158_1078_0432_CCR_24_4300
crossref_primary_10_5124_jkma_25_0061
crossref_primary_10_1101_gad_348523_121
crossref_primary_10_1007_s12672_023_00690_7
crossref_primary_10_3390_cancers12082077
crossref_primary_10_3390_molecules28031506
crossref_primary_10_1080_14728222_2021_1938541
crossref_primary_10_1016_j_yexmp_2024_104920
crossref_primary_10_1073_pnas_1914915116
crossref_primary_10_3389_fcell_2020_602352
crossref_primary_10_3389_fcell_2021_698296
crossref_primary_10_1038_s41467_023_40314_w
crossref_primary_10_1111_ans_17194
crossref_primary_10_1007_s15004_019_6744_1
crossref_primary_10_1126_science_adk0775
crossref_primary_10_1016_j_pbiomolbio_2025_02_003
crossref_primary_10_1002_cai2_160
crossref_primary_10_1016_j_pan_2024_08_014
crossref_primary_10_1371_journal_pone_0218642
crossref_primary_10_1002_adtp_202200079
crossref_primary_10_1038_s41571_023_00746_1
crossref_primary_10_1038_s41598_024_53145_6
crossref_primary_10_3390_cancers12123674
crossref_primary_10_3389_fonc_2023_1074445
crossref_primary_10_1097_JP9_0000000000000086
crossref_primary_10_1158_0008_5472_CAN_25_1085
crossref_primary_10_1016_j_tips_2022_03_005
crossref_primary_10_3390_cancers14112653
crossref_primary_10_1038_s41575_021_00463_z
crossref_primary_10_3390_cancers12113206
crossref_primary_10_1007_s11523_020_00751_9
crossref_primary_10_3390_cancers16132488
crossref_primary_10_1155_2021_2715694
crossref_primary_10_1096_fj_202302484RR
crossref_primary_10_3390_cimb46050294
crossref_primary_10_1038_s41392_022_01203_8
crossref_primary_10_1038_s41698_023_00455_z
crossref_primary_10_1515_med_2024_0906
crossref_primary_10_1186_s13550_021_00843_1
crossref_primary_10_1002_jhbp_1159
crossref_primary_10_1016_j_csbj_2024_09_032
crossref_primary_10_1016_j_ctrv_2021_102180
crossref_primary_10_1158_1078_0432_CCR_22_3493
crossref_primary_10_1016_j_ebiom_2020_102655
crossref_primary_10_1038_s41588_022_01134_8
crossref_primary_10_3390_diagnostics14050514
crossref_primary_10_1007_s15004_019_6745_0
crossref_primary_10_1016_j_soc_2021_06_003
crossref_primary_10_1097_JP9_0000000000000067
crossref_primary_10_1097_JP9_0000000000000189
crossref_primary_10_3390_ijms25179368
crossref_primary_10_3390_biomedicines12040865
crossref_primary_10_3390_cancers15051454
crossref_primary_10_1016_j_biomaterials_2025_123456
crossref_primary_10_3390_cancers15072134
crossref_primary_10_1158_2159_8290_CD_22_0876
crossref_primary_10_1016_j_heliyon_2024_e27679
crossref_primary_10_1016_j_tranon_2021_101107
crossref_primary_10_3390_cancers16040794
crossref_primary_10_1093_carcin_bgae056
crossref_primary_10_3389_fcell_2022_901207
crossref_primary_10_1016_j_apsb_2023_07_018
crossref_primary_10_3389_fonc_2021_775597
crossref_primary_10_1007_s13402_024_00939_5
crossref_primary_10_3389_fcell_2021_665161
crossref_primary_10_3389_fonc_2021_791946
crossref_primary_10_3390_cancers16030640
crossref_primary_10_1038_s41575_021_00486_6
Cites_doi 10.1038/s41436-018-0009-5
10.15252/emmm.201404827
10.1038/nm.3174
10.1016/j.gde.2013.12.001
10.1136/gutjnl-2016-313133
10.1101/198903
10.1093/jnci/djp020
10.1016/S1470-2045(16)30559-9
10.1136/gutjnl-2012-303108
10.1016/j.ccell.2018.02.003
10.1038/ncomms7744
10.1038/ng.3934
10.1200/JCO.2017.72.3502
10.1038/nature16965
10.1038/ng.3398
10.1158/1078-0432.CCR-17-0899
10.1158/2159-8290.CD-14-0617
10.1038/nm.2344
10.1158/0008-5472.CAN-16-0899
10.1053/j.gastro.2009.04.009
10.1038/sj.bjc.6601894
10.1053/j.gastro.2014.11.042
10.1371/journal.pmed.1001453
10.1038/nature14169
10.1172/JCI40045
10.1158/0008-5472.CAN-14-0155
10.1007/s00534-013-0610-6
10.1158/1078-0432.CCR-16-2411
10.1038/nm.4292
10.1038/35021093
10.1093/annonc/mdw192
10.1158/2159-8290.CD-18-0275
10.1038/nature10760
10.1038/nrc3723
10.1182/blood-2017-08-803353
10.1097/PAS.0000000000000533
10.1016/j.ejso.2018.10.024
10.1186/gm482
10.1038/nature07385
10.1038/nm.3175
10.18632/oncotarget.20492
10.1053/j.gastro.2013.08.053
10.1016/j.ccell.2015.09.020
10.1158/1078-0432.CCR-17-2994
10.1093/annonc/mdr561
10.1002/path.4310
10.1111/pcmr.12148
10.1016/j.ccell.2016.02.010
10.1002/path.4042
10.1158/1055-9965.EPI-15-1217
10.1038/modpathol.2014.100
10.1093/nar/gkq929
10.1371/journal.pone.0074380
10.1053/j.seminoncol.2016.09.002
10.1016/j.ejca.2005.04.044
10.1159/000441557
10.1136/gutjnl-2013-306202
10.1002/ijc.28765
10.1158/1078-0432.CCR-17-3099
10.1001/jamaoncol.2016.3916
10.1126/science.1171202
10.1038/nature15819
10.1093/bioinformatics/btt755
10.1038/nature12477
10.1016/j.ccell.2017.07.007
10.1016/j.ydbio.2006.06.046
10.1126/science.1235122
10.1016/j.ccr.2012.10.025
10.1038/nature08987
10.1093/nar/16.16.7773
10.1002/jso.23194
10.1038/nmeth.4407
10.2353/ajpath.2010.090899
10.1038/nature13385
10.1056/NEJMra031623
10.1126/scitranslmed.3002003
10.1097/MPA.0000000000000392
10.1136/gut.2010.236026
10.1136/gut.2008.171611
10.1053/j.gastro.2018.08.033
10.1056/NEJMoa1105535
10.1097/PAS.0000000000000169
10.1038/nm.4038
10.1111/pcmr.12388
10.1038/modpathol.3880332
10.1002/cncr.28863
10.1371/journal.pmed.1002223
10.3322/caac.21387
10.1007/s00439-011-1010-0
10.1093/jnci/djp466
10.1097/01.pas.0000126675.59108.80
10.1038/nrdp.2016.22
10.1016/j.celrep.2018.03.131
10.1126/science.1164368
10.1038/nature24462
10.1016/j.suc.2015.05.003
10.1016/S1470-2045(17)30679-4
10.1038/nature11547
10.1016/j.cell.2014.06.049
10.1053/j.gastro.2015.01.009
10.1002/humu.21633
10.1053/j.gastro.2015.07.041
10.1158/0008-5472.CAN-03-3823
10.1016/j.cell.2014.01.066
10.1016/j.ccell.2016.04.014
10.1038/35000501
10.1053/j.gastro.2016.09.060
10.1200/JCO.2008.17.7188
10.1038/nm.3967
10.1056/NEJM200103153441101
10.1136/gutjnl-2018-316151
10.1038/nature09454
ContentType Journal Article
Copyright Springer Nature Limited 2019
COPYRIGHT 2019 Nature Publishing Group
2019© Springer Nature Limited 2019
Copyright_xml – notice: Springer Nature Limited 2019
– notice: COPYRIGHT 2019 Nature Publishing Group
– notice: 2019© Springer Nature Limited 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41575-019-0109-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
ProQuest Central Student



MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1759-5053
EndPage 220
ExternalDocumentID A580380444
30718832
10_1038_s41575_019_0109_y
Genre Journal Article
Review
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: Medical Research Council
  grantid: MR/N005813/1
– fundername: Cancer Research UK
  grantid: 17263
– fundername: Pancreatic Cancer UK
  grantid: FLF2015_04_GLASGOW
GroupedDBID ---
0R~
29M
39C
3V.
53G
70F
7X7
88E
8FE
8FH
8FI
8FJ
AAEEF
AAQQT
AARCD
AASDW
AAWTL
AAWYQ
AAYZH
AAZLF
ABAWZ
ABJNI
ABLJU
ABUWG
ACGFS
ADBBV
AENEX
AFKRA
AFSHS
AGAYW
AGHTU
AHBCP
AHMBA
AHOSX
AHSBF
AIBTJ
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARMCB
AXYYD
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
DB5
EBS
EE.
EJD
EXGXG
F5P
FQGFK
FSGXE
FYUFA
HCIFZ
HMCUK
HZ~
IAO
IHR
IHW
INH
INR
ITC
LK8
M1P
M7P
NNMJJ
ODYON
OVD
PQQKQ
PROAC
PSQYO
RNR
RNT
RNTTT
SHXYY
SIXXV
SNYQT
SOJ
TAOOD
TBHMF
TDRGL
TEORI
TSG
UKHRP
AAYXX
ABFSG
ACSTC
AEZWR
AFANA
AFHIU
AGSTI
AHWEU
AIXLP
ALPWD
ATHPR
CITATION
CGR
CUY
CVF
ECM
EIF
NFIDA
NPM
PHGZT
PHGZM
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c470t-a2b1b1bcb1bd750a9b4dccfab7450019e7a66e6d90cf8ee5a78b93e64281f7c73
IEDL.DBID M7P
ISICitedReferencesCount 659
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000462486600008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1759-5045
1759-5053
IngestDate Thu Oct 02 20:16:39 EDT 2025
Tue Oct 07 06:59:08 EDT 2025
Sat Nov 29 13:20:20 EST 2025
Sat Nov 29 10:20:58 EST 2025
Thu May 22 21:24:26 EDT 2025
Thu Apr 03 07:00:56 EDT 2025
Sat Nov 29 01:32:47 EST 2025
Tue Nov 18 22:25:18 EST 2025
Fri Feb 21 02:37:03 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-a2b1b1bcb1bd750a9b4dccfab7450019e7a66e6d90cf8ee5a78b93e64281f7c73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0362-5597
PMID 30718832
PQID 2198554115
PQPubID 2042741
PageCount 14
ParticipantIDs proquest_miscellaneous_2179531637
proquest_journals_2198554115
gale_infotracmisc_A580380444
gale_infotracacademiconefile_A580380444
gale_healthsolutions_A580380444
pubmed_primary_30718832
crossref_primary_10_1038_s41575_019_0109_y
crossref_citationtrail_10_1038_s41575_019_0109_y
springer_journals_10_1038_s41575_019_0109_y
PublicationCentury 2000
PublicationDate 2019-04-01
PublicationDateYYYYMMDD 2019-04-01
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature reviews. Gastroenterology & hepatology
PublicationTitleAbbrev Nat Rev Gastroenterol Hepatol
PublicationTitleAlternate Nat Rev Gastroenterol Hepatol
PublicationYear 2019
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Rahib (CR9) 2014; 74
Jones (CR52) 2008; 321
Petersen (CR14) 2016; 43
Shindo (CR23) 2017; 35
Iacobuzio-Donahue (CR113) 2011; 61
Hall (CR117) 2016; 14
Iacobuzio-Donahue (CR45) 2009; 27
Cowley (CR61) 2013; 20
Perou (CR84) 2000; 406
Niu (CR43) 2014; 30
Smit (CR50) 1988; 16
Morran (CR67) 2014; 63
Decker, Goldman, Grasch, Sussel (CR90) 2006; 298
Planchard (CR65) 2017; 18
Vogelstein (CR92) 2013; 339
Hruban (CR33) 2004; 28
Steele (CR103) 2016; 29
Yurgelun (CR25) 2018
Kassahn (CR93) 2013; 8
Connor (CR121) 2017; 3
McBride (CR76) 2012; 227
Wolpin (CR19) 2009; 101
Hollingsworth, Biankin (CR5) 2015; 18
Basturk (CR31) 2014; 38
CR41
Furukawa (CR115) 2015; 5
De Sousa (CR86) 2013; 19
Waddell (CR55) 2015; 518
Biankin, Hudson (CR3) 2011; 130
Lowery (CR72) 2017; 23
Marisa (CR87) 2013; 10
Nones (CR95) 2014; 135
Brune (CR16) 2010; 102
Davies (CR78) 2017; 23
Miller (CR69) 2015; 7
Jones (CR17) 2009; 324
Siegel, Miller, Jemal (CR8) 2017; 67
Polak (CR77) 2017; 49
Swisher (CR82) 2017; 18
Collisson (CR89) 2011; 17
Bollag (CR64) 2010; 467
(CR60) 2017; 32
Slamon (CR63) 2001; 344
Basturk (CR32) 2015; 39
Kleeff (CR62) 2016; 2
Qian (CR49) 2018; 4
Aung (CR122) 2017; 24
Jiao (CR116) 2014; 232
Andricovich (CR110) 2018; 33
Swanton (CR6) 2016; 27
Moffitt (CR58) 2015; 47
Noll (CR99) 2016; 22
Habib (CR107) 2017; 14
Scarpa, Real, Luchini (CR36) 2018; 67
Chang, Grimmond, Evans, Biankin (CR74) 2014; 14
McWilliams (CR28) 2016; 45
Bailey (CR56) 2016; 531
Kardon, Thompson, Przygodzki, Heffess (CR30) 2001; 14
Biankin, Maitra (CR97) 2015; 28
Humphris (CR18) 2014; 120
Weissmueller (CR68) 2014; 157
Menzies (CR119) 2015; 28
Humphris (CR42) 2017; 152
Kim (CR112) 2017; 8
Chang, Grimmond, Biankin (CR54) 2014; 24
Humphris, Chang, Biankin (CR24) 2015; 148
Kloppel, Luttges (CR29) 2001; 85
Zhao (CR106) 2017; 130
Sadanandam (CR85) 2013; 19
Balachandran (CR35) 2017; 551
Hudson (CR1) 2010; 464
Alexandrov (CR13) 2013; 500
Puleo (CR98) 2018; 155
Biankin (CR40) 2009; 137
Forbes (CR80) 2011; 39
Jamieson, Chang, Biankin (CR91) 2015; 95
Sequist (CR114) 2011; 3
Springer (CR37) 2015; 149
CR7
Pishvaian, Brody (CR39) 2017; 31
Hu (CR20) 2018; 24
Witkiewicz (CR59) 2015; 6
Reid, Bagci, Adsay (CR38) 2013; 107
Biankin (CR53) 2012; 491
Morris, Cano, Sekine, Wang, Hebrok (CR102) 2010; 120
CR123
Delgiorno (CR109) 2014; 146
CR81
Foster (CR73) 2016; 29
Hoadley (CR96) 2014; 158
Agaimy (CR120) 2015; 28
(CR2) 2008; 455
Klein (CR15) 2004; 64
Brugge, Lauwers, Sahani, Fernandez-del Castillo, Warshaw (CR34) 2004; 351
Chou (CR70) 2013; 5
Dreyer (CR46) 2017; 44
Bamford (CR79) 2004; 91
Ledermann (CR66) 2012; 366
Aguirre (CR48) 2018; 8
(CR12) 2014; 511
Biankin, Piantadosi, Hollingsworth (CR4) 2015; 526
Sinha (CR108) 2017; 77
Lord, Ashworth (CR75) 2012; 481
Langer (CR27) 2009; 58
Humphris (CR47) 2012; 23
CR10
Alizadeh (CR83) 2000; 403
Candido (CR104) 2018; 23
Canto (CR26) 2013; 62
Grant (CR22) 2014; 148
Ryan, Hong, Bardeesy (CR11) 2014; 371
Dreyer, Chang, Bailey, Biankin (CR57) 2017; 23
Kopp (CR101) 2012; 22
Xu (CR105) 2010; 177
Botton (CR118) 2013; 26
Knudsen (CR100) 2017; 67
Garcea, Neal, Pattenden, Steward, Berry (CR44) 2005; 41
Sivakumar, de Santiago, Chlon, Markowetz (CR111) 2017; 14
Chmielecki (CR71) 2014; 4
Childs (CR21) 2016; 25
Guinney (CR88) 2015; 21
Song (CR94) 2012; 7
Jones (CR51) 2012; 33
A Sadanandam (109_CR85) 2013; 19
EA Collisson (109_CR89) 2011; 17
C Swanton (109_CR6) 2016; 27
S Sinha (109_CR108) 2017; 77
109_CR10
BW Miller (109_CR69) 2015; 7
DJ McBride (109_CR76) 2012; 227
VT Smit (109_CR50) 1988; 16
L Rahib (109_CR9) 2014; 74
AV Biankin (109_CR3) 2011; 130
N Waddell (109_CR55) 2015; 518
KE Delgiorno (109_CR109) 2014; 146
S Jones (109_CR52) 2008; 321
N Habib (109_CR107) 2017; 14
X Zhao (109_CR106) 2017; 130
MJ Cowley (109_CR61) 2013; 20
S Bamford (109_CR79) 2004; 91
109_CR81
K Nones (109_CR95) 2014; 135
J Kleeff (109_CR62) 2016; 2
AM Menzies (109_CR119) 2015; 28
The Cancer Genome Atlas Research Network (109_CR2) 2008; 455
DC Morran (109_CR67) 2014; 63
H Davies (109_CR78) 2017; 23
G Kloppel (109_CR29) 2001; 85
RH Hruban (109_CR33) 2004; 28
MB Yurgelun (109_CR25) 2018
AA Alizadeh (109_CR83) 2000; 403
ES Knudsen (109_CR100) 2017; 67
J Andricovich (109_CR110) 2018; 33
RA Moffitt (109_CR58) 2015; 47
B Niu (109_CR43) 2014; 30
AP Klein (109_CR15) 2004; 64
AK Witkiewicz (109_CR59) 2015; 6
109_CR123
LV Sequist (109_CR114) 2011; 3
A Agaimy (109_CR120) 2015; 28
JL Humphris (109_CR42) 2017; 152
S Sivakumar (109_CR111) 2017; 14
J Chmielecki (109_CR71) 2014; 4
The Cancer Genome Atlas Research Network (109_CR12) 2014; 511
D Planchard (109_CR65) 2017; 18
SB Dreyer (109_CR46) 2017; 44
G Garcea (109_CR44) 2005; 41
WR Brugge (109_CR34) 2004; 351
JL Humphris (109_CR18) 2014; 120
S Jones (109_CR17) 2009; 324
AJ Aguirre (109_CR48) 2018; 8
DK Chang (109_CR54) 2014; 24
RC Grant (109_CR22) 2014; 148
T Botton (109_CR118) 2013; 26
G Bollag (109_CR64) 2010; 467
S Song (109_CR94) 2012; 7
EM Noll (109_CR99) 2016; 22
MA Lowery (109_CR72) 2017; 23
DE Kardon (109_CR30) 2001; 14
SJ Hollingsworth (109_CR5) 2015; 18
F Puleo (109_CR98) 2018; 155
ZI Hu (109_CR20) 2018; 24
RL Siegel (109_CR8) 2017; 67
KA Hoadley (109_CR96) 2014; 158
TJ Hudson (109_CR1) 2010; 464
CW Steele (109_CR103) 2016; 29
Z Xu (109_CR105) 2010; 177
EJ Childs (109_CR21) 2016; 25
109_CR7
MD Reid (109_CR38) 2013; 107
AV Biankin (109_CR40) 2009; 137
T Furukawa (109_CR115) 2015; 5
A Chou (109_CR70) 2013; 5
P Langer (109_CR27) 2009; 58
109_CR41
SA Foster (109_CR73) 2016; 29
KS Kassahn (109_CR93) 2013; 8
O Basturk (109_CR32) 2015; 39
AV Biankin (109_CR53) 2012; 491
JL Humphris (109_CR47) 2012; 23
S Weissmueller (109_CR68) 2014; 157
S Jones (109_CR51) 2012; 33
J Guinney (109_CR88) 2015; 21
AV Biankin (109_CR97) 2015; 28
B Vogelstein (109_CR92) 2013; 339
RR McWilliams (109_CR28) 2016; 45
A Scarpa (109_CR36) 2018; 67
CA Iacobuzio-Donahue (109_CR113) 2011; 61
AV Biankin (109_CR4) 2015; 526
JC Hall (109_CR117) 2016; 14
SA Forbes (109_CR80) 2011; 39
ST Kim (109_CR112) 2017; 8
NB Jamieson (109_CR91) 2015; 95
GM Petersen (109_CR14) 2016; 43
MJ Pishvaian (109_CR39) 2017; 31
DK Chang (109_CR74) 2014; 14
J Ledermann (109_CR66) 2012; 366
DP Ryan (109_CR11) 2014; 371
P Polak (109_CR77) 2017; 49
VP Balachandran (109_CR35) 2017; 551
LB Alexandrov (109_CR13) 2013; 500
J Humphris (109_CR24) 2015; 148
CJ Lord (109_CR75) 2012; 481
K Decker (109_CR90) 2006; 298
JB Candido (109_CR104) 2018; 23
K Shindo (109_CR23) 2017; 35
Y Jiao (109_CR116) 2014; 232
ZR Qian (109_CR49) 2018; 4
MI Canto (109_CR26) 2013; 62
KL Aung (109_CR122) 2017; 24
DJ Slamon (109_CR63) 2001; 344
O Basturk (109_CR31) 2014; 38
EMF Sousa De (109_CR86) 2013; 19
The Cancer Genome Atlas Research Network (109_CR60) 2017; 32
CA Iacobuzio-Donahue (109_CR45) 2009; 27
KA Brune (109_CR16) 2010; 102
JPt Morris (109_CR102) 2010; 120
BM Wolpin (109_CR19) 2009; 101
P Bailey (109_CR56) 2016; 531
L Marisa (109_CR87) 2013; 10
S Springer (109_CR37) 2015; 149
SB Dreyer (109_CR57) 2017; 23
JL Kopp (109_CR101) 2012; 22
EM Swisher (109_CR82) 2017; 18
CM Perou (109_CR84) 2000; 406
AA Connor (109_CR121) 2017; 3
References_xml – volume: 39
  start-page: 1730
  year: 2015
  end-page: 1741
  ident: CR32
  article-title: A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas
  publication-title: Am. J. Surg. Pathol.
– volume: 101
  start-page: 424
  year: 2009
  end-page: 431
  ident: CR19
  article-title: ABO blood group and the risk of pancreatic cancer
  publication-title: J. Natl Cancer Inst.
– volume: 45
  start-page: 311
  year: 2016
  end-page: 316
  ident: CR28
  article-title: Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case-control consortium (PanC4) analysis
  publication-title: Pancreas
– volume: 8
  start-page: 1096
  year: 2018
  end-page: 1111
  ident: CR48
  article-title: Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
  publication-title: Cancer Discov.
– volume: 28
  start-page: 411
  year: 2015
  end-page: 413
  ident: CR97
  article-title: Subtyping pancreatic cancer
  publication-title: Cancer Cell
– volume: 339
  start-page: 1546
  year: 2013
  end-page: 1558
  ident: CR92
  article-title: Cancer genome landscapes
  publication-title: Science
– volume: 3
  start-page: 774
  year: 2017
  end-page: 783
  ident: CR121
  article-title: Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma
  publication-title: JAMA Oncol.
– volume: 29
  start-page: 477
  year: 2016
  end-page: 493
  ident: CR73
  article-title: Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2
  publication-title: Cancer Cell
– volume: 67
  start-page: 7
  year: 2017
  end-page: 30
  ident: CR8
  article-title: Cancer statistics, 2017
  publication-title: CA Cancer J. Clin.
– volume: 137
  start-page: 558
  year: 2009
  end-page: 568
  ident: CR40
  article-title: Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer
  publication-title: Gastroenterology
– volume: 344
  start-page: 783
  year: 2001
  end-page: 792
  ident: CR63
  article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
  publication-title: N. Engl. J. Med.
– volume: 17
  start-page: 500
  year: 2011
  end-page: 503
  ident: CR89
  article-title: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
  publication-title: Nat. Med.
– volume: 526
  start-page: 361
  year: 2015
  end-page: 370
  ident: CR4
  article-title: Patient-centric trials for therapeutic development in precision oncology
  publication-title: Nature
– volume: 14
  year: 2016
  ident: CR117
  article-title: Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin
  publication-title: J. Transl Med.
– volume: 26
  start-page: 845
  year: 2013
  end-page: 851
  ident: CR118
  article-title: Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
  publication-title: Pigment Cell Melanoma Res.
– volume: 49
  start-page: 1476
  year: 2017
  end-page: 1486
  ident: CR77
  article-title: A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
  publication-title: Nat. Genet.
– volume: 14
  start-page: 955
  year: 2017
  end-page: 958
  ident: CR107
  article-title: Massively parallel single-nucleus RNA-seq with DroNc-seq
  publication-title: Nat. Methods
– volume: 511
  start-page: 543
  year: 2014
  end-page: 550
  ident: CR12
  article-title: Comprehensive molecular profiling of lung adenocarcinoma
  publication-title: Nature
– volume: 3
  start-page: 75ra26
  year: 2011
  ident: CR114
  article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
  publication-title: Sci. Transl Med.
– volume: 20
  start-page: 549
  year: 2013
  end-page: 556
  ident: CR61
  article-title: Understanding pancreatic cancer genomes
  publication-title: J. Hepatobiliary Pancreat. Sci.
– volume: 35
  start-page: 3382
  year: 2017
  end-page: 3390
  ident: CR23
  article-title: Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma
  publication-title: J. Clin. Oncol.
– volume: 5
  year: 2015
  ident: CR115
  article-title: Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas
  publication-title: Sci. Rep.
– volume: 14
  start-page: 291
  year: 2014
  end-page: 292
  ident: CR74
  article-title: Mining the genomes of exceptional responders
  publication-title: Nat. Rev. Cancer
– volume: 44
  start-page: 1838
  year: 2017
  ident: CR46
  article-title: Precision oncology in surgery: patient selection biomarkers for operable pancreatic cancer [abstract 10]
  publication-title: Eur. J. Surg. Oncol.
– volume: 518
  start-page: 495
  year: 2015
  end-page: 501
  ident: CR55
  article-title: Whole genomes redefine the mutational landscape of pancreatic cancer
  publication-title: Nature
– volume: 33
  start-page: 512
  year: 2018
  end-page: 526
  ident: CR110
  article-title: Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors
  publication-title: Cancer Cell
– volume: 531
  start-page: 47
  year: 2016
  end-page: 52
  ident: CR56
  article-title: Genomic analyses identify molecular subtypes of pancreatic cancer
  publication-title: Nature
– volume: 467
  start-page: 596
  year: 2010
  end-page: 599
  ident: CR64
  article-title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
  publication-title: Nature
– volume: 18
  start-page: 75
  year: 2017
  end-page: 87
  ident: CR82
  article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
  publication-title: Lancet Oncol.
– volume: 10
  year: 2013
  ident: CR87
  article-title: Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
  publication-title: PLOS Med.
– volume: 2
  start-page: 16022
  year: 2016
  ident: CR62
  article-title: Pancreatic cancer
  publication-title: Nat. Rev. Dis. Primers
– volume: 324
  start-page: 217
  year: 2009
  ident: CR17
  article-title: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene
  publication-title: Science
– volume: 77
  start-page: 1868
  year: 2017
  end-page: 1879
  ident: CR108
  article-title: PanIN neuroendocrine cells promote tumorigenesis via neuronal cross-talk
  publication-title: Cancer Res.
– volume: 500
  start-page: 415
  year: 2013
  end-page: 421
  ident: CR13
  article-title: Signatures of mutational processes in human cancer
  publication-title: Nature
– volume: 28
  start-page: 248
  year: 2015
  end-page: 260
  ident: CR120
  article-title: Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes
  publication-title: Mod. Pathol.
– volume: 4
  year: 2018
  ident: CR49
  article-title: Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma
  publication-title: JAMA Oncol.
– volume: 157
  start-page: 382
  year: 2014
  end-page: 394
  ident: CR68
  article-title: Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling
  publication-title: Cell
– volume: 130
  start-page: 2762
  year: 2017
  end-page: 2773
  ident: CR106
  article-title: Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells
  publication-title: Blood
– volume: 28
  start-page: 977
  year: 2004
  end-page: 987
  ident: CR33
  article-title: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms
  publication-title: Am. J. Surg. Pathol.
– volume: 21
  start-page: 1350
  year: 2015
  end-page: 1356
  ident: CR88
  article-title: The consensus molecular subtypes of colorectal cancer
  publication-title: Nat. Med.
– volume: 120
  start-page: 3669
  year: 2014
  end-page: 3675
  ident: CR18
  article-title: Clinical and pathologic features of familial pancreatic cancer
  publication-title: Cancer
– ident: CR10
– volume: 64
  start-page: 2634
  year: 2004
  end-page: 2638
  ident: CR15
  article-title: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds
  publication-title: Cancer Res.
– volume: 23
  start-page: 1638
  year: 2017
  end-page: 1646
  ident: CR57
  article-title: Pancreatic cancer genomes: implications for clinical management and therapeutic development
  publication-title: Clin. Cancer Res.
– volume: 18
  start-page: 1307
  year: 2017
  end-page: 1316
  ident: CR65
  article-title: Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
  publication-title: Lancet Oncol.
– volume: 403
  start-page: 503
  year: 2000
  end-page: 511
  ident: CR83
  article-title: Distinct types of diffuse large B cell lymphoma identified by gene expression profiling
  publication-title: Nature
– volume: 148
  start-page: 496
  year: 2015
  end-page: 498
  ident: CR24
  article-title: Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing
  publication-title: Gastroenterology
– volume: 29
  start-page: 832
  year: 2016
  end-page: 845
  ident: CR103
  article-title: CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma
  publication-title: Cancer Cell
– volume: 23
  start-page: 517
  year: 2017
  end-page: 525
  ident: CR78
  article-title: HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
  publication-title: Nat. Med.
– volume: 14
  start-page: 443
  year: 2001
  end-page: 451
  ident: CR30
  article-title: Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases
  publication-title: Mod. Pathol.
– volume: 152
  start-page: 68
  year: 2017
  end-page: 74
  ident: CR42
  article-title: Hypermutation in pancreatic cancer
  publication-title: Gastroenterology
– ident: CR123
– volume: 62
  start-page: 339
  year: 2013
  end-page: 347
  ident: CR26
  article-title: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
  publication-title: Gut
– volume: 8
  year: 2013
  ident: CR93
  article-title: Somatic point mutation calling in low cellularity tumors
  publication-title: PLOS ONE
– volume: 6
  year: 2015
  ident: CR59
  article-title: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
  publication-title: Nat. Commun.
– volume: 406
  start-page: 747
  year: 2000
  end-page: 752
  ident: CR84
  article-title: Molecular portraits of human breast tumours
  publication-title: Nature
– volume: 321
  start-page: 1801
  year: 2008
  end-page: 1806
  ident: CR52
  article-title: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
  publication-title: Science
– volume: 23
  start-page: 1713
  year: 2012
  end-page: 1722
  ident: CR47
  article-title: The prognostic and predictive value of serum CA19.9 in pancreatic cancer
  publication-title: Ann. Oncol.
– volume: 135
  start-page: 1110
  year: 2014
  end-page: 1118
  ident: CR95
  article-title: Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling
  publication-title: Int. J. Cancer
– volume: 58
  start-page: 1410
  year: 2009
  end-page: 1418
  ident: CR27
  article-title: Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer
  publication-title: Gut
– volume: 16
  start-page: 7773
  year: 1988
  end-page: 7782
  ident: CR50
  article-title: KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
  publication-title: Nucleic Acids Res.
– volume: 33
  start-page: 100
  year: 2012
  end-page: 103
  ident: CR51
  article-title: Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
  publication-title: Hum. Mut.
– volume: 38
  start-page: 437
  year: 2014
  end-page: 447
  ident: CR31
  article-title: Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases
  publication-title: Am. J. Surg. Pathol.
– ident: CR41
– volume: 351
  start-page: 1218
  year: 2004
  end-page: 1226
  ident: CR34
  article-title: Cystic neoplasms of the pancreas
  publication-title: N. Engl. J. Med.
– volume: 464
  start-page: 993
  year: 2010
  end-page: 998
  ident: CR1
  article-title: International network of cancer genome projects
  publication-title: Nature
– volume: 5
  year: 2013
  ident: CR70
  article-title: Clinical and molecular characterization of HER2 amplified-pancreatic cancer
  publication-title: Genome Med.
– volume: 32
  start-page: 185
  year: 2017
  end-page: 203
  ident: CR60
  article-title: Integrated genomic characterization of pancreatic ductal adenocarcinoma
  publication-title: Cancer Cell
– volume: 30
  start-page: 1015
  year: 2014
  end-page: 1016
  ident: CR43
  article-title: MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
  publication-title: Bioinformatics
– year: 2018
  ident: CR25
  article-title: Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
  publication-title: Genet. Med.
  doi: 10.1038/s41436-018-0009-5
– volume: 130
  start-page: 79
  year: 2011
  end-page: 91
  ident: CR3
  article-title: Somatic variation and cancer: therapies lost in the mix
  publication-title: Hum. Genet.
– volume: 67
  start-page: 1561
  year: 2018
  end-page: 1563
  ident: CR36
  article-title: Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management
  publication-title: Gut
– volume: 18
  start-page: 338
  year: 2015
  end-page: 348
  ident: CR5
  article-title: The challenges of precision oncology drug development and implementation
  publication-title: Public Health Genomics
– volume: 95
  start-page: 919
  year: 2015
  end-page: 934
  ident: CR91
  article-title: Cancer genetics and implications for clinical management
  publication-title: Surg. Clin. North Am.
– volume: 7
  year: 2012
  ident: CR94
  article-title: qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles
  publication-title: PLOS ONE
– volume: 63
  start-page: 1481
  year: 2014
  end-page: 1489
  ident: CR67
  article-title: Targeting mTOR dependency in pancreatic cancer
  publication-title: Gut
– volume: 27
  start-page: 1806
  year: 2009
  end-page: 1813
  ident: CR45
  article-title: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
  publication-title: J. Clin. Oncol.
– volume: 41
  start-page: 2213
  year: 2005
  end-page: 2236
  ident: CR44
  article-title: Molecular prognostic markers in pancreatic cancer: a systematic review
  publication-title: Eur. J. Cancer
– volume: 25
  start-page: 1185
  year: 2016
  end-page: 1191
  ident: CR21
  article-title: Association of common susceptibility variants of pancreatic cancer in higher-risk patients: a PACGENE study
  publication-title: Cancer Epidemiol. Biomarkers Prev.
– volume: 24
  start-page: 1344
  year: 2017
  end-page: 1354
  ident: CR122
  article-title: Genomics-driven precision medicine for advanced pancreatic cancer — early results from the COMPASS trial
  publication-title: Clin. Cancer Res.
– volume: 455
  start-page: 1061
  year: 2008
  end-page: 1068
  ident: CR2
  article-title: Comprehensive genomic characterization defines human glioblastoma genes and core pathways
  publication-title: Nature
– volume: 14
  year: 2017
  ident: CR111
  article-title: Master regulators of oncogenic KRAS response in pancreatic cancer: an integrative network biology analysis
  publication-title: PLOS Med.
– volume: 4
  start-page: 1398
  year: 2014
  end-page: 1405
  ident: CR71
  article-title: Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes
  publication-title: Cancer Discov.
– volume: 23
  start-page: 1448
  year: 2018
  end-page: 1460
  ident: CR104
  article-title: CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype
  publication-title: Cell Rep.
– volume: 102
  start-page: 119
  year: 2010
  end-page: 126
  ident: CR16
  article-title: Importance of age of onset in pancreatic cancer kindreds
  publication-title: J. Natl Cancer Inst.
– volume: 43
  start-page: 548
  year: 2016
  end-page: 553
  ident: CR14
  article-title: Familial pancreatic cancer
  publication-title: Semin. Oncol.
– volume: 23
  start-page: 6094
  year: 2017
  end-page: 6100
  ident: CR72
  article-title: Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype
  publication-title: Clin. Cancer Res.
– volume: 227
  start-page: 446
  year: 2012
  end-page: 455
  ident: CR76
  article-title: Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
  publication-title: J. Pathol.
– volume: 120
  start-page: 508
  year: 2010
  end-page: 520
  ident: CR102
  article-title: Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice
  publication-title: J. Clin. Invest.
– volume: 28
  start-page: 607
  year: 2015
  end-page: 610
  ident: CR119
  article-title: Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
  publication-title: Pigment Cell Melanoma Res.
– ident: CR81
– volume: 366
  start-page: 1382
  year: 2012
  end-page: 1392
  ident: CR66
  article-title: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
  publication-title: N. Engl. J. Med.
– volume: 148
  start-page: 556
  year: 2014
  end-page: 564
  ident: CR22
  article-title: Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer
  publication-title: Gastroenterology
– volume: 7
  start-page: 1063
  year: 2015
  end-page: 1076
  ident: CR69
  article-title: Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy
  publication-title: EMBO Mol. Med.
– volume: 149
  start-page: 1501
  year: 2015
  end-page: 1510
  ident: CR37
  article-title: A combination of molecular markers and clinical features improve the classification of pancreatic cysts
  publication-title: Gastroenterology
– volume: 232
  start-page: 428
  year: 2014
  end-page: 435
  ident: CR116
  article-title: Whole-exome sequencing of pancreatic neoplasms with acinar differentiation
  publication-title: J. Pathol.
– volume: 551
  start-page: 512
  year: 2017
  end-page: 516
  ident: CR35
  article-title: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
  publication-title: Nature
– volume: 146
  start-page: 233
  year: 2014
  end-page: 244
  ident: CR109
  article-title: Identification and manipulation of biliary metaplasia in pancreatic tumors
  publication-title: Gastroenterology
– volume: 177
  start-page: 2585
  year: 2010
  end-page: 2596
  ident: CR105
  article-title: Role of pancreatic stellate cells in pancreatic cancer metastasis
  publication-title: Am. J. Pathol.
– volume: 22
  start-page: 737
  year: 2012
  end-page: 750
  ident: CR101
  article-title: Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma
  publication-title: Cancer Cell
– volume: 47
  start-page: 1168
  year: 2015
  end-page: 1178
  ident: CR58
  article-title: Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
  publication-title: Nat. Genet.
– volume: 24
  start-page: 74
  year: 2014
  end-page: 81
  ident: CR54
  article-title: Pancreatic cancer genomics
  publication-title: Curr. Opin. Genet. Dev.
– volume: 19
  start-page: 619
  year: 2013
  end-page: 625
  ident: CR85
  article-title: A colorectal cancer classification system that associates cellular phenotype and responses to therapy
  publication-title: Nat. Med.
– volume: 24
  start-page: 1326
  year: 2018
  end-page: 1336
  ident: CR20
  article-title: Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations
  publication-title: Clin. Cancer Res.
– volume: 298
  start-page: 415
  year: 2006
  end-page: 429
  ident: CR90
  article-title: Gata6 is an important regulator of mouse pancreas development
  publication-title: Dev. Biol.
– volume: 91
  start-page: 355
  year: 2004
  end-page: 358
  ident: CR79
  article-title: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
  publication-title: Br. J. Cancer
– volume: 481
  start-page: 287
  year: 2012
  end-page: 294
  ident: CR75
  article-title: The DNA damage response and cancer therapy
  publication-title: Nature
– volume: 27
  start-page: 1443
  year: 2016
  end-page: 1448
  ident: CR6
  article-title: Consensus on precision medicine for metastatic cancers: a report from the MAP conference
  publication-title: Ann. Oncol.
– volume: 371
  start-page: 2140
  year: 2014
  end-page: 2141
  ident: CR11
  article-title: Pancreatic adenocarcinoma
  publication-title: N. Engl. J. Med.
– volume: 107
  start-page: 67
  year: 2013
  end-page: 77
  ident: CR38
  article-title: Histopathologic assessment of pancreatic cancer: does one size fit all?
  publication-title: J. Surg. Oncol.
– volume: 19
  start-page: 614
  year: 2013
  end-page: 618
  ident: CR86
  article-title: Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
  publication-title: Nat. Med.
– volume: 8
  start-page: 77415
  year: 2017
  end-page: 77423
  ident: CR112
  article-title: Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
  publication-title: Oncotarget
– volume: 155
  start-page: 1999
  year: 2018
  end-page: 2013
  ident: CR98
  article-title: Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
  publication-title: Gastroenterology
– volume: 491
  start-page: 399
  year: 2012
  end-page: 405
  ident: CR53
  article-title: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
  publication-title: Nature
– volume: 31
  start-page: 159
  year: 2017
  end-page: 166
  ident: CR39
  article-title: Therapeutic implications of molecular subtyping for pancreatic cancer
  publication-title: Oncology
– volume: 74
  start-page: 2913
  year: 2014
  end-page: 2921
  ident: CR9
  article-title: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States
  publication-title: Cancer Res.
– ident: CR7
– volume: 22
  start-page: 278
  year: 2016
  end-page: 287
  ident: CR99
  article-title: CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
  publication-title: Nat. Med.
– volume: 158
  start-page: 929
  year: 2014
  end-page: 944
  ident: CR96
  article-title: Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
  publication-title: Cell
– volume: 39
  start-page: D945
  year: 2011
  end-page: D950
  ident: CR80
  article-title: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
  publication-title: Nucleic Acids Res.
– volume: 61
  start-page: 1085
  year: 2011
  end-page: 1094
  ident: CR113
  article-title: Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project
  publication-title: Gut
– volume: 85
  start-page: 219
  year: 2001
  end-page: 228
  ident: CR29
  article-title: WHO-classification 2000: exocrine pancreatic tumors
  publication-title: Verh. Dtsch. Ges. Pathol.
– volume: 67
  start-page: 508
  year: 2017
  end-page: 520
  ident: CR100
  article-title: Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
  publication-title: Gut
– volume: 85
  start-page: 219
  year: 2001
  ident: 109_CR29
  publication-title: Verh. Dtsch. Ges. Pathol.
– volume: 7
  start-page: 1063
  year: 2015
  ident: 109_CR69
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.201404827
– volume: 19
  start-page: 614
  year: 2013
  ident: 109_CR86
  publication-title: Nat. Med.
  doi: 10.1038/nm.3174
– volume: 24
  start-page: 74
  year: 2014
  ident: 109_CR54
  publication-title: Curr. Opin. Genet. Dev.
  doi: 10.1016/j.gde.2013.12.001
– volume: 67
  start-page: 508
  year: 2017
  ident: 109_CR100
  publication-title: Gut
  doi: 10.1136/gutjnl-2016-313133
– ident: 109_CR123
  doi: 10.1101/198903
– volume: 101
  start-page: 424
  year: 2009
  ident: 109_CR19
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djp020
– volume: 18
  start-page: 75
  year: 2017
  ident: 109_CR82
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30559-9
– volume: 62
  start-page: 339
  year: 2013
  ident: 109_CR26
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-303108
– volume: 33
  start-page: 512
  year: 2018
  ident: 109_CR110
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.02.003
– volume: 6
  year: 2015
  ident: 109_CR59
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms7744
– volume: 49
  start-page: 1476
  year: 2017
  ident: 109_CR77
  publication-title: Nat. Genet.
  doi: 10.1038/ng.3934
– volume: 35
  start-page: 3382
  year: 2017
  ident: 109_CR23
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.72.3502
– volume: 531
  start-page: 47
  year: 2016
  ident: 109_CR56
  publication-title: Nature
  doi: 10.1038/nature16965
– volume: 47
  start-page: 1168
  year: 2015
  ident: 109_CR58
  publication-title: Nat. Genet.
  doi: 10.1038/ng.3398
– volume: 23
  start-page: 6094
  year: 2017
  ident: 109_CR72
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-0899
– volume: 4
  start-page: 1398
  year: 2014
  ident: 109_CR71
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-14-0617
– volume: 17
  start-page: 500
  year: 2011
  ident: 109_CR89
  publication-title: Nat. Med.
  doi: 10.1038/nm.2344
– volume: 77
  start-page: 1868
  year: 2017
  ident: 109_CR108
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-0899
– volume: 137
  start-page: 558
  year: 2009
  ident: 109_CR40
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.04.009
– volume: 91
  start-page: 355
  year: 2004
  ident: 109_CR79
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6601894
– volume: 148
  start-page: 556
  year: 2014
  ident: 109_CR22
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.11.042
– volume: 10
  year: 2013
  ident: 109_CR87
  publication-title: PLOS Med.
  doi: 10.1371/journal.pmed.1001453
– volume: 518
  start-page: 495
  year: 2015
  ident: 109_CR55
  publication-title: Nature
  doi: 10.1038/nature14169
– volume: 120
  start-page: 508
  year: 2010
  ident: 109_CR102
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI40045
– volume: 74
  start-page: 2913
  year: 2014
  ident: 109_CR9
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-0155
– volume: 20
  start-page: 549
  year: 2013
  ident: 109_CR61
  publication-title: J. Hepatobiliary Pancreat. Sci.
  doi: 10.1007/s00534-013-0610-6
– volume: 23
  start-page: 1638
  year: 2017
  ident: 109_CR57
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2411
– volume: 23
  start-page: 517
  year: 2017
  ident: 109_CR78
  publication-title: Nat. Med.
  doi: 10.1038/nm.4292
– ident: 109_CR81
– volume: 406
  start-page: 747
  year: 2000
  ident: 109_CR84
  publication-title: Nature
  doi: 10.1038/35021093
– ident: 109_CR10
– volume: 27
  start-page: 1443
  year: 2016
  ident: 109_CR6
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw192
– volume: 8
  start-page: 1096
  year: 2018
  ident: 109_CR48
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0275
– volume: 481
  start-page: 287
  year: 2012
  ident: 109_CR75
  publication-title: Nature
  doi: 10.1038/nature10760
– volume: 14
  start-page: 291
  year: 2014
  ident: 109_CR74
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3723
– volume: 130
  start-page: 2762
  year: 2017
  ident: 109_CR106
  publication-title: Blood
  doi: 10.1182/blood-2017-08-803353
– volume: 39
  start-page: 1730
  year: 2015
  ident: 109_CR32
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0000000000000533
– volume: 44
  start-page: 1838
  year: 2017
  ident: 109_CR46
  publication-title: Eur. J. Surg. Oncol.
  doi: 10.1016/j.ejso.2018.10.024
– volume: 5
  year: 2013
  ident: 109_CR70
  publication-title: Genome Med.
  doi: 10.1186/gm482
– volume: 455
  start-page: 1061
  year: 2008
  ident: 109_CR2
  publication-title: Nature
  doi: 10.1038/nature07385
– volume: 19
  start-page: 619
  year: 2013
  ident: 109_CR85
  publication-title: Nat. Med.
  doi: 10.1038/nm.3175
– volume: 8
  start-page: 77415
  year: 2017
  ident: 109_CR112
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20492
– volume: 146
  start-page: 233
  year: 2014
  ident: 109_CR109
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.08.053
– volume: 28
  start-page: 411
  year: 2015
  ident: 109_CR97
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.09.020
– volume: 24
  start-page: 1344
  year: 2017
  ident: 109_CR122
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-2994
– volume: 23
  start-page: 1713
  year: 2012
  ident: 109_CR47
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdr561
– volume: 232
  start-page: 428
  year: 2014
  ident: 109_CR116
  publication-title: J. Pathol.
  doi: 10.1002/path.4310
– volume: 26
  start-page: 845
  year: 2013
  ident: 109_CR118
  publication-title: Pigment Cell Melanoma Res.
  doi: 10.1111/pcmr.12148
– volume: 29
  start-page: 477
  year: 2016
  ident: 109_CR73
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.02.010
– volume: 227
  start-page: 446
  year: 2012
  ident: 109_CR76
  publication-title: J. Pathol.
  doi: 10.1002/path.4042
– volume: 25
  start-page: 1185
  year: 2016
  ident: 109_CR21
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-15-1217
– volume: 28
  start-page: 248
  year: 2015
  ident: 109_CR120
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2014.100
– volume: 39
  start-page: D945
  year: 2011
  ident: 109_CR80
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkq929
– volume: 8
  year: 2013
  ident: 109_CR93
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0074380
– volume: 43
  start-page: 548
  year: 2016
  ident: 109_CR14
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2016.09.002
– volume: 41
  start-page: 2213
  year: 2005
  ident: 109_CR44
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2005.04.044
– volume: 18
  start-page: 338
  year: 2015
  ident: 109_CR5
  publication-title: Public Health Genomics
  doi: 10.1159/000441557
– volume: 63
  start-page: 1481
  year: 2014
  ident: 109_CR67
  publication-title: Gut
  doi: 10.1136/gutjnl-2013-306202
– ident: 109_CR41
– volume: 135
  start-page: 1110
  year: 2014
  ident: 109_CR95
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.28765
– volume: 371
  start-page: 2140
  year: 2014
  ident: 109_CR11
  publication-title: N. Engl. J. Med.
– volume: 24
  start-page: 1326
  year: 2018
  ident: 109_CR20
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3099
– volume: 3
  start-page: 774
  year: 2017
  ident: 109_CR121
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2016.3916
– volume: 324
  start-page: 217
  year: 2009
  ident: 109_CR17
  publication-title: Science
  doi: 10.1126/science.1171202
– volume: 526
  start-page: 361
  year: 2015
  ident: 109_CR4
  publication-title: Nature
  doi: 10.1038/nature15819
– volume: 30
  start-page: 1015
  year: 2014
  ident: 109_CR43
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btt755
– volume: 5
  year: 2015
  ident: 109_CR115
  publication-title: Sci. Rep.
– volume: 500
  start-page: 415
  year: 2013
  ident: 109_CR13
  publication-title: Nature
  doi: 10.1038/nature12477
– volume: 32
  start-page: 185
  year: 2017
  ident: 109_CR60
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.07.007
– volume: 14
  year: 2016
  ident: 109_CR117
  publication-title: J. Transl Med.
– volume: 298
  start-page: 415
  year: 2006
  ident: 109_CR90
  publication-title: Dev. Biol.
  doi: 10.1016/j.ydbio.2006.06.046
– volume: 339
  start-page: 1546
  year: 2013
  ident: 109_CR92
  publication-title: Science
  doi: 10.1126/science.1235122
– volume: 22
  start-page: 737
  year: 2012
  ident: 109_CR101
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.10.025
– volume: 464
  start-page: 993
  year: 2010
  ident: 109_CR1
  publication-title: Nature
  doi: 10.1038/nature08987
– volume: 16
  start-page: 7773
  year: 1988
  ident: 109_CR50
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/16.16.7773
– volume: 107
  start-page: 67
  year: 2013
  ident: 109_CR38
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.23194
– volume: 14
  start-page: 955
  year: 2017
  ident: 109_CR107
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4407
– volume: 177
  start-page: 2585
  year: 2010
  ident: 109_CR105
  publication-title: Am. J. Pathol.
  doi: 10.2353/ajpath.2010.090899
– volume: 511
  start-page: 543
  year: 2014
  ident: 109_CR12
  publication-title: Nature
  doi: 10.1038/nature13385
– volume: 351
  start-page: 1218
  year: 2004
  ident: 109_CR34
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra031623
– volume: 3
  start-page: 75ra26
  year: 2011
  ident: 109_CR114
  publication-title: Sci. Transl Med.
  doi: 10.1126/scitranslmed.3002003
– volume: 45
  start-page: 311
  year: 2016
  ident: 109_CR28
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000000392
– volume: 61
  start-page: 1085
  year: 2011
  ident: 109_CR113
  publication-title: Gut
  doi: 10.1136/gut.2010.236026
– volume: 58
  start-page: 1410
  year: 2009
  ident: 109_CR27
  publication-title: Gut
  doi: 10.1136/gut.2008.171611
– volume: 155
  start-page: 1999
  year: 2018
  ident: 109_CR98
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.08.033
– year: 2018
  ident: 109_CR25
  publication-title: Genet. Med.
  doi: 10.1038/s41436-018-0009-5
– volume: 366
  start-page: 1382
  year: 2012
  ident: 109_CR66
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1105535
– volume: 38
  start-page: 437
  year: 2014
  ident: 109_CR31
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0000000000000169
– volume: 31
  start-page: 159
  year: 2017
  ident: 109_CR39
  publication-title: Oncology
– volume: 22
  start-page: 278
  year: 2016
  ident: 109_CR99
  publication-title: Nat. Med.
  doi: 10.1038/nm.4038
– volume: 28
  start-page: 607
  year: 2015
  ident: 109_CR119
  publication-title: Pigment Cell Melanoma Res.
  doi: 10.1111/pcmr.12388
– volume: 14
  start-page: 443
  year: 2001
  ident: 109_CR30
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.3880332
– volume: 120
  start-page: 3669
  year: 2014
  ident: 109_CR18
  publication-title: Cancer
  doi: 10.1002/cncr.28863
– volume: 14
  year: 2017
  ident: 109_CR111
  publication-title: PLOS Med.
  doi: 10.1371/journal.pmed.1002223
– volume: 67
  start-page: 7
  year: 2017
  ident: 109_CR8
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21387
– volume: 130
  start-page: 79
  year: 2011
  ident: 109_CR3
  publication-title: Hum. Genet.
  doi: 10.1007/s00439-011-1010-0
– volume: 102
  start-page: 119
  year: 2010
  ident: 109_CR16
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djp466
– volume: 28
  start-page: 977
  year: 2004
  ident: 109_CR33
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/01.pas.0000126675.59108.80
– volume: 2
  start-page: 16022
  year: 2016
  ident: 109_CR62
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/nrdp.2016.22
– volume: 23
  start-page: 1448
  year: 2018
  ident: 109_CR104
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2018.03.131
– volume: 321
  start-page: 1801
  year: 2008
  ident: 109_CR52
  publication-title: Science
  doi: 10.1126/science.1164368
– volume: 551
  start-page: 512
  year: 2017
  ident: 109_CR35
  publication-title: Nature
  doi: 10.1038/nature24462
– volume: 95
  start-page: 919
  year: 2015
  ident: 109_CR91
  publication-title: Surg. Clin. North Am.
  doi: 10.1016/j.suc.2015.05.003
– volume: 4
  year: 2018
  ident: 109_CR49
  publication-title: JAMA Oncol.
– volume: 18
  start-page: 1307
  year: 2017
  ident: 109_CR65
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30679-4
– volume: 491
  start-page: 399
  year: 2012
  ident: 109_CR53
  publication-title: Nature
  doi: 10.1038/nature11547
– volume: 158
  start-page: 929
  year: 2014
  ident: 109_CR96
  publication-title: Cell
  doi: 10.1016/j.cell.2014.06.049
– volume: 148
  start-page: 496
  year: 2015
  ident: 109_CR24
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.01.009
– volume: 33
  start-page: 100
  year: 2012
  ident: 109_CR51
  publication-title: Hum. Mut.
  doi: 10.1002/humu.21633
– volume: 149
  start-page: 1501
  year: 2015
  ident: 109_CR37
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.07.041
– volume: 64
  start-page: 2634
  year: 2004
  ident: 109_CR15
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-03-3823
– volume: 157
  start-page: 382
  year: 2014
  ident: 109_CR68
  publication-title: Cell
  doi: 10.1016/j.cell.2014.01.066
– volume: 29
  start-page: 832
  year: 2016
  ident: 109_CR103
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.04.014
– volume: 403
  start-page: 503
  year: 2000
  ident: 109_CR83
  publication-title: Nature
  doi: 10.1038/35000501
– volume: 152
  start-page: 68
  year: 2017
  ident: 109_CR42
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.09.060
– volume: 27
  start-page: 1806
  year: 2009
  ident: 109_CR45
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.17.7188
– volume: 21
  start-page: 1350
  year: 2015
  ident: 109_CR88
  publication-title: Nat. Med.
  doi: 10.1038/nm.3967
– volume: 344
  start-page: 783
  year: 2001
  ident: 109_CR63
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM200103153441101
– volume: 67
  start-page: 1561
  year: 2018
  ident: 109_CR36
  publication-title: Gut
  doi: 10.1136/gutjnl-2018-316151
– volume: 7
  year: 2012
  ident: 109_CR94
  publication-title: PLOS ONE
– volume: 467
  start-page: 596
  year: 2010
  ident: 109_CR64
  publication-title: Nature
  doi: 10.1038/nature09454
– ident: 109_CR7
SSID ssj0065539
Score 2.685862
SecondaryResourceType review_article
Snippet Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes....
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 207
SubjectTerms 631/337/2019
692/4020/1503/1712/1713
692/4028/67/68
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedicine
Cancer therapies
Carcinoma, Pancreatic Ductal - diagnosis
Carcinoma, Pancreatic Ductal - genetics
Carcinoma, Pancreatic Ductal - metabolism
Carcinoma, Pancreatic Ductal - therapy
Care and treatment
Clinical Decision-Making - methods
Decision making
Development and progression
Gastroenterology
Genetic aspects
Genetic Markers
Genotype
Health aspects
Hepatology
Humans
Medicine
Medicine & Public Health
Morbidity
Pancreatic cancer
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - therapy
Patients
Prognosis
Review Article
Risk Assessment
Taxonomy
Title Molecular subtypes of pancreatic cancer
URI https://link.springer.com/article/10.1038/s41575-019-0109-y
https://www.ncbi.nlm.nih.gov/pubmed/30718832
https://www.proquest.com/docview/2198554115
https://www.proquest.com/docview/2179531637
Volume 16
WOSCitedRecordID wos000462486600008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1759-5053
  dateEnd: 20241209
  omitProxy: false
  ssIdentifier: ssj0065539
  issn: 1759-5045
  databaseCode: M7P
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1da9sw8Fg_KH3Z1q4f3rLUhUJhRdSJY0t6Gt1o2UMbQtlK3oQky1AoSRsnhf773sly0hTWl2LsF51kS_dp3ekO4Kg0vFekpmTGyi7rOc2ZNK5krmNReXI04f3xsZtL3u-L4VAOwoZbFcIqG5noBXUxtrRHfoqcRRFVaMD8vH9gVDWKvKuhhMYKrFGWhNSH7g0aSZxnma8khhpSsgxtl8armYrTChUXp7A1ihZKJHta0kuvpfML9fTKX-rV0MWn907gM3wMBmh8VlPMFnxwo23YuAou9i9wfNUUzI2rmaEd2ioelzEKjdq-tLElQpnswL-L87-__7BQTYHZHk-mTHdNBy-Ld4FmgpamV1hbakRWRoae4zrPXV7IxJbCuUxzYWTq6P-kU3LL011YHY1Hbh9ibRIcEg03jc1GSEM6LtHI3ojwrpERJM1aKhtSjVPFizvlXd6pUPXyK3ytouVXTxH8mHe5r_NsvAV8QAhS9VHROY-qs0wgPGXAi-DYQxCX4putDocN8Psp39USZGsJErnLLjc32FSBuyu1QGUEh_Nm6kkRayM3nhEMlyjf8pRHsFcTz3xiKFc7AkVpBCcNNS0G_--sv779Kd9gs-vJmaKKWrA6nczcd1i3j9PbatKGFT7k_inasPbrvD-4bntmeQbXCRNY
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3dT9swED8BQ4wXNj42AmwECYQEspomTRw_IIS2IRBtxQNDfTO240hIqGVNC-o_tb9xd_mCIo03HlCUJ18cJ777_c722Qewm2reSgKdMm2Ez1pWcSa0TZltGiRPji58vn3sus273bjXE5cz8LfaC0NhlRUm5kCdDAzNkTfQsiiiCh2Y4_s_jLJG0epqlUKjUIsLO3nEIVt2dP4T-3fP909_Xf04Y2VWAWZa3Bsx5esmXgbvBOlSCd1KjEkVNjokh8dyFUU2SoRn0tjaUPFYi8CSn95MueEB1jsLHxDHOYWQ8V49wIvCMM9chowsWIi-UrWKGsSNDImSU5gcRSd5gk2mePAlGzyjwxfrszntnX56bz_sMyyVDrZ7UljEMszY_gosdMoQglXY71QJgd1srGkGOnMHqYugWPjPxjVkCMM1-P0mzfwCc_1B366Dq7SHVaJjqrBYx0ITh3sK4QsV2tfCAa_qO2nKo9Qpo8edzJf0g1gW3S3xtZK6W04cOKgfuS_OEXlNeJsUQhZbYWsMkidhjPJ0wp8D-7kEoRC-2ahyMwW2n87zmpLcmpJE9DDTxZX2yBK9MvmkOg7s1MX0JEXk9e1gTDJcIH5HAXfga6Gs9YchbzRjpAoHDivtfar8v1-98XpTtuHj2VWnLdvn3YtNWPRzU6IIqi2YGw3H9hvMm4fRbTb8nhulCzdvrdT_AJF2bzw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NgSZeGF9jYYMFCTQJZDVNmjh-mNDEqJj6oT4A2puxHUeaNLWjaTf1X-Ov250Td7QSe9sDivLki2PXv7vfNT7fAbwvNe8UiS6ZNiJmHas4E9qWzLYNkidHF94dH_vZ58NhfnYmRhvwx5-FobBKbxOdoS4mhr6Rt1CzKKIKHZhW2YRFjE66ny9_M6ogRTutvpxGDZGeXVzj37fq6PQE1_pDHHe_fv_yjTUVBpjp8GjGVKzbeBm8C6ROJXSnMKZUOIGUnB_LVZbZrBCRKXNrU8VzLRJLPnu75IYn2O8DeMgpabkLGxx5FsjS1FUxQ3YWLEW_ye-oJnmrQtLkFDJHkUqRYIsVTlxnhr-ocW2v1lFgd_t__vGewpPG8Q6Pa015Bht2_By2Bk1owQs4HPhCwWE11_RlugonZYjGsvarTWhIQaYv4ce9DHMHNseTsd2FUOkIu0SHVWGzzoUmbo8UmjUEeqxFAJFfR2maFOtU6eNCuq3-JJf10kt8raSll4sAPi4fuazzi9wlfEDgkPUR2aVtksdpjvKU-S-AQydB1gnfbFRzyALHT3m-ViT3VyTRqpjVZo8k2Vi1St7CKIB3y2Z6kiL1xnYyJxku0K5nCQ_gVQ3c5cSQT9o5UkgAnzySbzv_56xf3z2UA9hCLMv-6bC3B49jp1UUWLUPm7Pp3L6BR-Zqdl5N3zr9DOHXfWP6Bvg7eAo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+subtypes+of+pancreatic+cancer&rft.jtitle=Nature+reviews.+Gastroenterology+%26+hepatology&rft.au=Collisson%2C+Eric+A&rft.au=Bailey%2C+Peter&rft.au=Chang%2C+David+K&rft.au=Biankin%2C+Andrew+V&rft.date=2019-04-01&rft.issn=1759-5053&rft.eissn=1759-5053&rft.volume=16&rft.issue=4&rft.spage=207&rft_id=info:doi/10.1038%2Fs41575-019-0109-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-5045&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-5045&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-5045&client=summon